Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Celecoxib in Triple Negative Breast Cancer: NCT07104266 Clinical Landscape Report 2026
28 September 2026
NCT07104266 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imdatifan in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07097935 Clinical Landscape Report 2026
28 September 2026
NCT07097935 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT07101614 Clinical Landscape Report 2026
28 September 2026
NCT07101614 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lomustine in Glioblastoma Multiforme: NCT07100730 Clinical Landscape Report 2026
28 September 2026
NCT07100730 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4152199 in Follicular Lymphoma: NCT07101328 Clinical Landscape Report 2026
28 September 2026
NCT07101328 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT07103447 Clinical Landscape Report 2026
28 September 2026
NCT07103447 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCD-236 in Recurrent Triple-Negative Breast Carcinoma: NCT07108309 Clinical Landscape Report 2026
28 September 2026
NCT07108309 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT07107217 Clinical Landscape Report 2026
28 September 2026
NCT07107217 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rilvegostomig in Metastatic Solid Tumor: NCT07115043 Clinical Landscape Report 2026
28 September 2026
NCT07115043 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab Rezetecan in PD-L1 positive Triple Negative Breast Cancer: NCT07111832 Clinical Landscape Report 2026
28 September 2026
NCT07111832 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Humanized CD70-Targeted CAR-T Cell Incorporating TLR2(Tongji Hospital) in Advanced Renal Cell Carcinoma: NCT07113977 Clinical Landscape Report 2026
28 September 2026
NCT07113977 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Palbociclib in Metastatic Renal Cell Carcinoma: NCT07123090 Clinical Landscape Report 2026
28 September 2026
NCT07123090 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.